The BALANCE setback is the most significant GLP-1 policy development since the Section 232 tariff announcement. CMS shelved its five-year Medicare Part D demonstration for GLP-1 weight loss coverage after CVS Health declined to participate and UnitedHealth Group expressed reluctance. The program required insurers covering 80% of certain beneficiaries to opt in by April 20. Without the two largest Medicare insurers, that threshold could not be met. CMS pivoted: the Bridge interim program, originally set to expire at the end of 2026, now extends through December 31, 2027. Under Bridge, the government pays directly for GLP-1 coverage at a $50 copay for eligible Part D beneficiaries, absorbing the cost rather than shifting it to insurers. For Lilly and Novo, this is a mixed outcome—patients still get access starting July 2026, but through a less durable mechanism. Truist estimated up to $500 million in negative impact on peak incretin Medicare Part D sales. Meanwhile, Merck quietly landed a significant approval: Idvynso (doravirine/islatravir), the first non-INSTI, tenofovir-free, once-daily two-drug HIV regimen to beat Biktarvy in a head-to-head trial, was approved a week ahead of its PDUFA date. J&J kicked off pharma earnings season above $15 billion in first-quarter drug sales, and Lilly made its fourth acquisition announcement of the month.
Top Story: Medicare Shelves BALANCE GLP-1 Program After Insurer Pushback
What Happened: CMS announced on Tuesday that it is shelving the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) program, the administration’s proposed five-year Medicare Part D demonstration for GLP-1 coverage. The decision came after CVS Health declined to participate and UnitedHealth Group expressed reluctance, according to Bloomberg. The program required insurers covering 80% of certain beneficiaries to opt in by the April 20 deadline. Without the two largest insurers, that threshold could not be met.
The Structural Problem That Killed BALANCE
BALANCE was designed as the mechanism through which the administration would deliver on its promise to make GLP-1s accessible to Medicare beneficiaries for weight loss. Medicare is currently barred by law from covering weight-loss drugs. Both BALANCE and Bridge function as demonstration programs to work around that statutory restriction.
The BALANCE design would have created a structure in which CMS negotiated pricing directly with manufacturers and private Medicare insurers covered the drugs as a benefit. The $50 copay was the headline. The infrastructure was the challenge.
Insurers balked because BALANCE shifted financial risk to them. Under the current Part D structure, insurers manage drug costs through formulary design, prior authorization, and rebates. BALANCE would have required them to cover GLP-1s for weight loss at a negotiated price without the usual cost-management tools that Part D insurers use to control spending. CVS calculated that the economics did not work. UnitedHealth’s chief of government programs told investors there are “notable challenges and outstanding questions with the currently planned structure.”
Without buy-in from the two largest Medicare insurers, the program cannot function. Axios called it a “shift in course” for the administration.
The Bridge Extension: Government Pays Directly
CMS responded by extending the Medicare GLP-1 Bridge program through December 31, 2027. Under Bridge, CMS pays directly for GLP-1 coverage for eligible Part D beneficiaries at a $50 copay, operating outside the normal Part D benefit structure. The program was originally set to expire at the end of 2026.
Bridge launches on July 1, 2026, giving Medicare beneficiaries access to GLP-1s for weight loss for the first time. The key difference from BALANCE: under Bridge, the government absorbs the cost rather than requiring private insurers to carry the financial risk. For patients, the near-term effect is minimal—the same $50 copay, the same July 2026 start date. For the federal budget, the implications are substantially different.
The Impact on Lilly and Novo
For both companies, this is a mixed outcome. An Eli Lilly spokesperson said the company “supports the intent of the BALANCE pilot” and that the Bridge extension “provides an important opportunity to continue reaching patients.” LLY and NVO shares dipped on the news.
Truist estimated up to $500 million in negative impact on peak incremental Medicare Part D sales for Zepbound and Foundayo. The concern is not near-term access—Bridge provides that—but long-term durability. Bridge is a government-funded stopgap that could face political headwinds, budget constraints, or expiration at the end of 2027 without renewal. BALANCE, by contrast, was designed as a five-year program with insurer participation that would have been more difficult to reverse.
What Comes Next
The path forward is likely legislative. Medicare’s statutory prohibition on covering weight-loss drugs predates the GLP-1 era and was never designed to address drugs with the clinical profile and cost structure of modern obesity therapeutics. Changing that law would allow permanent GLP-1 coverage through the normal Part D benefit, with insurers managing costs the way they manage other drug categories. But that requires an act of Congress, which has not been politically viable despite bipartisan interest in expanding obesity treatment access.
The BALANCE failure may force the issue. If Bridge enrollment and costs demonstrate that Medicare beneficiaries benefit from GLP-1 access—and the clinical data on cardiovascular outcomes, diabetes prevention, and healthcare cost reduction support the economic case—the pressure on Congress to act legislatively will intensify. But for now, the most durable path to permanent Medicare GLP-1 coverage has been shelved, and the industry is left with a stopgap that expires in 20 months.
Our Pro brief analyzes what the insurer pushback means for long-term GLP-1 Medicare economics, how Bridge costs could scale if uptake follows the commercial trajectory, and why Congress may ultimately need to change the law. [Details below.]
FDA Approves Merck’s Idvynso for HIV, a Week Ahead of PDUFA
What Happened: The FDA approved Idvynso (doravirine 100mg/islatravir 0.25mg) on April 21, a week before its April 28 PDUFA date. Idvynso is a once-daily, single-tablet, two-drug regimen for adults with virologically suppressed HIV-1 (RNA <50 copies/mL) on a stable antiretroviral regimen with no history of virologic failure and no known doravirine resistance.
What Makes Idvynso Different
Idvynso is the first and only non-INSTI (integrase strand transfer inhibitor), tenofovir-free, once-daily complete two-drug regimen approved for HIV. The current standard of care is Gilead’s Biktarvy, a three-drug INSTI-based regimen that dominates the HIV treatment market.
The differentiation is not superiority—it is optionality. In the Phase 3 Trial 052, patients switching from Biktarvy to Idvynso maintained viral suppression at non-inferior rates. The drug did not beat Biktarvy. It matched it while offering a fundamentally different pharmacological profile.
Non-INSTI: Some patients and physicians prefer avoiding integrase inhibitors due to concerns about weight gain and potential neuropsychiatric effects that have been reported with the INSTI class.
Tenofovir-free: Eliminates long-term bone density and renal concerns associated with tenofovir-containing regimens, which are a component of Biktarvy and most other current HIV treatment options.
Two-drug simplicity: One fewer active ingredient than Biktarvy’s three-drug combination.
Novel mechanism: Islatravir uses a dual mechanism—translocation inhibition and delayed chain termination—that distinguishes it from conventional nucleoside reverse transcriptase inhibitors (NRTIs).
The Commercial Challenge
Biktarvy works extremely well. Non-inferiority is a necessary but not sufficient condition for taking share from a dominant market leader. Idvynso needs to find patients who are specifically dissatisfied with their current regimen or who have clinical reasons to avoid INSTIs or tenofovir. That is a meaningful but defined patient population rather than a mass-market opportunity.
BioSpace noted that Idvynso “will also help Merck diversify as loss of exclusivity looms over its top-selling product, the mega-blockbuster cancer drug Keytruda.” For Merck, every new revenue stream matters as loss of exclusivity approaches. Idvynso will not replace Keytruda revenue, but it adds a durable franchise in a therapeutic area where Merck has not previously competed at the front-line level.
Our Pro brief analyzes whether a two-drug non-INSTI regimen can take meaningful share from Biktarvy’s dominant position, how the tenofovir-free and INSTI-free profile maps to specific patient segments, and what Idvynso means for Merck’s Keytruda diversification strategy. [Details below.]
Corporate Developments
J&J Beats Q1 Estimates, Surpasses $15B in Drug Sales
Johnson & Johnson kicked off pharma earnings season with first-quarter results that exceeded Wall Street expectations, surpassing $15 billion in pharmaceutical segment sales. The company’s growing multiple myeloma franchise—Darzalex, Tecvayli, and Talvey—was a primary growth driver. BioPharma Dive noted J&J also set “an ambitious goal” for the year ahead.
Why This Matters: J&J’s myeloma-driven beat signals that oncology franchise building is paying off across the industry. The $15 billion-plus pharmaceutical segment performance suggests that the patent cliff fears dominating M&A strategy have not yet materialized in actual quarterly earnings. The myeloma portfolio—spanning three distinct mechanisms—illustrates the value of building therapeutic area depth rather than relying on a single blockbuster.
Lilly Acquires CrossBridge Bio for Up to $300M
Eli Lilly acquired CrossBridge Bio, a Texas-based biotech, for up to $300 million. The deal adds dual-payload ADC technology to Lilly’s oncology pipeline. This follows the Kelonia acquisition announced on Monday and adds to the Orna ($2.4 billion, February) and Centessa ($7.8 billion, March) acquisitions. Lilly’s 2026 M&A total now exceeds $17.5 billion. This is the fourth acquisition announcement Lilly has made in April alone.
Biogen Consolidates Felzartamab Rights for $850M
Biogen consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma. The deal closes a complex 10-year licensing arrangement and gives Biogen complete control of the antibody program. Felzartamab is the CD38 antibody for kidney transplant rejection that Biogen acquired through the HI-Bio deal—and a key strategic rationale behind the Apellis acquisition, which provided the nephrology commercial team to support felzartamab’s launch.
Strategic Themes
1. The BALANCE Failure Exposes the Structural Problem with Medicare GLP-1 Coverage
Medicare cannot cover weight-loss drugs by statute. BALANCE was an attempt to work around that restriction through a demonstration program that required insurer cooperation. Insurers refused to cooperate. Bridge bypasses the insurers entirely but puts the government on the hook for all costs. Neither approach creates permanent, sustainable coverage. Until Congress changes the underlying law, Medicare GLP-1 access will remain dependent on temporary programs that can expire, be defunded, or be politically reversed. The BALANCE failure does not eliminate patient access—Bridge provides that starting July—but it eliminates the most durable path to long-term coverage.
2. Merck’s Diversification Beyond Keytruda Now Has a Second Leg
Idvynso gives Merck a competitive entry in HIV alongside its Keytruda-dominated oncology portfolio. With Keytruda facing loss of exclusivity, every new revenue stream matters. HIV is a durable therapeutic area with long treatment duration, high adherence rates, and proven commercial models. Idvynso will not replace Keytruda revenue, but it adds a franchise with predictable economics in a market where Gilead has demonstrated that standard-of-care HIV drugs can generate billions annually.
3. Lilly’s April Deal Pace Is Extraordinary Even by 2026 Standards
Four acquisition announcements in a single month: Kelonia (up to $7 billion), CrossBridge Bio (up to $300 million), and the continued integration of Orna ($2.4 billion) and Centessa ($7.8 billion). Total 2026 M&A now exceeds $17.5 billion. The pace reflects a company that has the balance sheet to sustain aggressive capital deployment, the strategic conviction to diversify beyond GLP-1, and the organizational confidence to run multiple integrations simultaneously. Whether the execution matches the ambition will be determined over the next 12 to 24 months.
4. Bridge Launches in July—and the Clock Is Already Ticking
Medicare beneficiaries will access GLP-1s for weight loss at a $50 copay starting July 1, 2026. That is a meaningful expansion of the addressable patient population for Lilly and Novo. But Bridge expires December 31, 2027, creating a finite window that could constrain prescriber and patient willingness to start long-term therapy. Physicians may hesitate to initiate chronic GLP-1 treatment through a program that has an expiration date—a behavioral dynamic that could suppress Bridge enrollment below what an open-ended coverage policy would generate.
Frequently Asked Questions
What is the BALANCE program, and why was it shelved?
BALANCE was a five-year Medicare Part D demonstration designed to provide GLP-1 coverage for weight loss. It required private Medicare insurers covering 80% of certain beneficiaries to opt in. CVS Health declined and UnitedHealth Group expressed reluctance, preventing the program from meeting its participation threshold. CMS shelved it and extended the Bridge interim program instead.
What is the Bridge program, and how does it work?
Bridge is a Medicare demonstration program in which CMS pays directly for GLP-1 coverage at a $50 copay for eligible Part D beneficiaries. Unlike BALANCE, Bridge does not require insurer participation—the government absorbs the costs. Bridge launches July 1, 2026 and now extends through December 31, 2027.
How does this affect Lilly and Novo?
Patients still get access starting July 2026 through Bridge. The concern is long-term durability. Truist estimated up to $500 million in negative impact on peak incremental Medicare Part D sales. Bridge is a government-funded stopgap with an expiration date, not the five-year insurer-backed program BALANCE was designed to be. LLY and NVO shares dipped on the news.
What is Idvynso, and how does it compare to Biktarvy?
Idvynso (doravirine/islatravir) is the first non-INSTI, tenofovir-free, once-daily two-drug HIV regimen. In a Phase 3 head-to-head trial, patients switching from Biktarvy to Idvynso maintained viral suppression at non-inferior rates. The differentiation is optionality rather than superiority—Idvynso avoids INSTI-class concerns (weight gain, neuropsychiatric effects) and tenofovir-related bone and kidney risks.
How did J&J perform in Q1 earnings?
J&J surpassed $15 billion in first-quarter pharmaceutical segment sales, beating Wall Street estimates. The multiple myeloma franchise (Darzalex, Tecvayli, Talvey) was the primary growth driver. BioPharma Dive noted the company also set ambitious full-year goals.
What did Lilly acquire with CrossBridge Bio?
Lilly acquired CrossBridge Bio for up to $300 million, adding dual-payload ADC technology to its oncology pipeline. This is Lilly’s fourth acquisition announcement in April and brings 2026 M&A total above $17.5 billion.
What is the Biogen felzartamab deal?
Biogen paid $850 million to TJ Biopharma to consolidate full global rights to felzartamab, a CD38 antibody for kidney transplant rejection. The deal closes a complex 10-year licensing arrangement and gives Biogen complete control of the program, which was a key strategic rationale behind the Apellis acquisition that provided the nephrology commercial team for felzartamab’s launch.
Will Congress need to change the law for permanent Medicare GLP-1 coverage?
Likely yes. Medicare is statutorily prohibited from covering weight-loss drugs. Both BALANCE and Bridge are demonstration programs designed to work around that restriction. Without legislative action, Medicare GLP-1 access will remain dependent on temporary programs that can expire or be defunded. The BALANCE failure may increase political pressure on Congress to act, but legislative change has not been politically viable to date despite bipartisan interest.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
BALANCE vs. Bridge: The Long-Term GLP-1 Medicare Calculus. We analyze what the insurer pushback means for the durability of Medicare GLP-1 coverage, how Bridge costs could scale if uptake follows the commercial trajectory, and why the path forward likely requires Congress to change the statutory prohibition on weight-loss drug coverage.
Idvynso’s Path to Share. We assess whether a two-drug non-INSTI regimen can take meaningful share from Biktarvy’s dominant position, map the patient segments most likely to switch, and model what Idvynso adds to Merck’s revenue diversification as Keytruda faces loss of exclusivity.
Q1 Earnings Scorecard: J&J Sets the Tone. We break down the myeloma-driven beat, what $15 billion in drug sales signals for the broader earnings cycle, and the key questions for upcoming reports from Novo (oral Wegovy revenue), Lilly (Foundayo launch, M&A commentary), and Merck (Idvynso guidance, Keytruda trajectory).
Plus: Bridge enrollment projections, Biogen felzartamab consolidation analysis, Lilly $17.5B M&A integration assessment, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
